Is Jardiance Approved for Heart Failure?
Yes, Jardiance (empagliflozin) is FDA-approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure, regardless of ejection fraction (including preserved, reduced, or mid-range). This approval covers both type 2 diabetes patients and those without diabetes.[1]
How Does Jardiance Work in Heart Failure?
Jardiance is an SGLT2 inhibitor that blocks glucose reabsorption in the kidneys, promoting its excretion in urine. In heart failure, it reduces fluid overload, lowers cardiac workload, and improves outcomes through mechanisms like natriuresis, reduced inflammation, and better myocardial energetics. Trials showed it cuts hospitalization risk by about 20-30%.[1][2]
Key Clinical Trials Backing This Use
- EMPEROR-Reduced (2020): In HFrEF patients (ejection fraction ≤40%), Jardiance reduced cardiovascular death or hospitalization by 25% vs. placebo.[2]
- EMPEROR-Preserved (2021): In HFpEF patients (ejection fraction >40%), it cut the same composite endpoint by 21%.[2]
- EMPA-REG OUTCOME (2015): Initial diabetes trial that first signaled heart failure benefits, with 35% reduction in hospitalization.[1]
These led to label expansions in 2021 and 2022 for broader heart failure use.
Who Can Take It and When?
Eligible adults include:
- Heart failure with reduced ejection fraction (HFrEF, ≤40%).
- Heart failure with preserved ejection fraction (HFpEF, >40%).
- Heart failure with mildly reduced ejection fraction (HFmrEF, 41-49%).
No diabetes required. It's added to standard therapy like ACE inhibitors or beta-blockers. Not for type 1 diabetes or severe kidney disease (eGFR <20 mL/min).[1]
Common Side Effects and Risks
Patients report urinary tract infections (9-10%), genital infections (5-6%), dehydration, and rare ketoacidosis. In heart failure trials, volume depletion occurred in 10-12% but serious events were low. Monitor kidney function and blood pressure.[1][2] Black box warning for lower limb amputation risk from diabetes trials.
How Does It Compare to Other SGLT2 Inhibitors?
| Drug | Heart Failure Approvals | Key Trial Edge |
|------|--------------------------|---------------|
| Jardiance (empagliflozin) | HFrEF, HFpEF, HFmrEF | Strongest data across ejection fractions[2] |
| Farxiga (dapagliflozin) | Similar (HFrEF, HFpEF) | DAPA-HF showed 26% HFrEF benefit[3] |
| Invokana (canagliflozin) | HFrEF only | Less broad data[3] |
All class members work similarly; guidelines (ACC/AHA 2022) recommend them interchangeably as first-line add-ons.[4]
Cost and Access
Monthly cost: $500-600 without insurance. Covered by most plans for approved uses; patient assistance via Boehringer Ingelheim. Generic unavailable until patent expiry around 2028-2033 (check DrugPatentWatch.com for updates).[5]
[1]: FDA Label - Jardiance (empagliflozin), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204629s033lbl.pdf
[2]: NEJM - EMPEROR Trials, https://www.nejm.org/doi/full/10.1056/NEJMoa1911303
[3]: NEJM - DAPA-HF, https://www.nejm.org/doi/full/10.1056/NEJMoa1911306
[4]: ACC/AHA 2022 HF Guidelines, https://www.jacc.org/doi/10.1016/j.jacc.2021.12.012
[5]: DrugPatentWatch.com - Jardiance Patents, https://www.drugpatentwatch.com/p/tradename/JARDIANCE